NCT02775422

Brief Summary

Comparison of the sensibility and specificity of 3 different serological tests and evaluation of chicken pox immunity in pregnant women. Secondary goals :

  • Correlation memory / Immunity;
  • Prevalence of VZV immunity in pregnant women;
  • Evaluation of cellular and humoral immunity in cases with discrepancy between tests or between test and memory;
  • Evaluation of acceptability of vaccination in the post partum period in non immune patients. Methods Not randomized prospective study, Number of patients : 400 Duration : 36 months Inclusion criteria : pregnant women \>18years old, agree to participate (written consent) Exclusion criteria: auto immune disease, HIV +, grafted patients

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
308

participants targeted

Target at P75+ for not_applicable pregnancy

Timeline
Completed

Started Mar 2015

Longer than P75 for not_applicable pregnancy

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 30, 2015

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

May 12, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 17, 2016

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 26, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 26, 2020

Completed
Last Updated

August 25, 2020

Status Verified

August 1, 2019

Enrollment Period

5.3 years

First QC Date

May 12, 2016

Last Update Submit

August 21, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Rate sensitivity and specificity in negative and dubious zone for the assessment of the serology of anti VZV immunity

    35 weeks

Secondary Outcomes (2)

  • frequency of immunity detecting depending on whether the patient remember having varicella, have been in contact with next of kin with varicella or been vaccinated against varicella or not

    up to 35 weeks

  • Percentage of women accepting the vaccination in case of negative history

    day during the first visit

Study Arms (1)

Pregnant women

EXPERIMENTAL

Pregnant women

Biological: Serological Test s for the Virus Chicken Pox Virus

Interventions

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Pregnant women aged over 18
  • Affiliated to a social protection scheme or women benefiting from such a regime
  • Women who gived a writing consent

You may not qualify if:

  • Women with a maternal disease: autoimmune disease (systemic lupus erythematosus, antiphospholipid syndrome, insulin dependent diabetes, autoimmune thyroiditis ..), it takes an immunosuppressive treatment or not.
  • HIV-positive women
  • Garfted women whatever organ

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hopital Foch

Suresnes, 92150, France

Location

Related Publications (25)

  • LAFORET EG, LYNCH CL Jr. Multiple congenital defects following maternal varicella; report of a case. N Engl J Med. 1947 Apr 10;236(15):534-7. doi: 10.1056/NEJM194704102361504. No abstract available.

    PMID: 20293114BACKGROUND
  • Alkalay AL, Pomerance JJ, Rimoin DL. Fetal varicella syndrome. J Pediatr. 1987 Sep;111(3):320-3. doi: 10.1016/s0022-3476(87)80447-x. No abstract available.

    PMID: 3625399BACKGROUND
  • SAUERBREI A. Fetales varizellen syndrom. Monatsschr kinderheiledkd 2003;151:209-213.

    BACKGROUND
  • Miller E, Cradock-Watson JE, Ridehalgh MK. Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus. Lancet. 1989 Aug 12;2(8659):371-3. doi: 10.1016/s0140-6736(89)90547-3.

    PMID: 2569560BACKGROUND
  • ENDERS G. Varicella and herpes zoster in pregnancy and the newborn. . Varicella-zoster virus and clinical management. Arvin AM and Gershon AA, eds; UK: Cambridge University Press 2000:317-347.

    BACKGROUND
  • MIRLESSE V. Varicelle et grossesse. Les virus transmissibles de la mère à l'enfant. Denis F. Ed John Libey Eurotext, In Montrouge 1999:252-269.

    BACKGROUND
  • Khoshnood B, Debruyne M, Lancon F, Emery C, Fagnani F, Durand I, Floret D. Seroprevalence of varicella in the French population. Pediatr Infect Dis J. 2006 Jan;25(1):41-4. doi: 10.1097/01.inf.0000195636.43584.bb.

    PMID: 16395101BACKGROUND
  • Wu MF, Yang YW, Lin WY, Chang CY, Soon MS, Liu CE. Varicella zoster virus infection among healthcare workers in Taiwan: seroprevalence and predictive value of history of varicella infection. J Hosp Infect. 2012 Feb;80(2):162-7. doi: 10.1016/j.jhin.2011.11.011. Epub 2011 Dec 19.

    PMID: 22188630BACKGROUND
  • Vandersmissen G, Moens G, Vranckx R, de Schryver A, Jacques P. Occupational risk of infection by varicella zoster virus in Belgian healthcare workers: a seroprevalence study. Occup Environ Med. 2000 Sep;57(9):621-6. doi: 10.1136/oem.57.9.621.

    PMID: 10935943BACKGROUND
  • Alp E, Cevahir F, Gokahmetoglu S, Demiraslan H, Doganay M. Prevaccination screening of health-care workers for immunity to measles, rubella, mumps, and varicella in a developing country: What do we save? J Infect Public Health. 2012 Apr;5(2):127-32. doi: 10.1016/j.jiph.2011.11.003. Epub 2012 Jan 18.

    PMID: 22541258BACKGROUND
  • Almuneef M, Memish ZA, Abbas ME, Balkhy HH. Screening healthcare workers for varicella-zoster virus: can we trust the history? Infect Control Hosp Epidemiol. 2004 Jul;25(7):595-8. doi: 10.1086/502445.

    PMID: 15301033BACKGROUND
  • Saadatian-Elahi M, Mekki Y, Del Signore C, Lina B, Derrough T, Caulin E, Thierry J, Vanhems P. Seroprevalence of varicella antibodies among pregnant women in Lyon-France. Eur J Epidemiol. 2007;22(6):405-9. doi: 10.1007/s10654-007-9136-z. Epub 2007 May 30.

    PMID: 17534728BACKGROUND
  • Reignier F, Romano L, Thiry N, Beutels P, Van Damme P, Fau C, Gaspard C, Mamoux V, Zanetti A, Floret D. [Varicella-zoster virus seroprevalence in nursery and day-care workers in Lyon (France)]. Med Mal Infect. 2005 Apr;35(4):192-6. doi: 10.1016/j.medmal.2005.01.007. French.

    PMID: 15914287BACKGROUND
  • Dashraath P, Ong ES, Lee VJ. Seroepidemiology of varicella and the reliability of a self-reported history of varicella infection in Singapore military recruits. Ann Acad Med Singap. 2007 Aug;36(8):636-41.

    PMID: 17767333BACKGROUND
  • Fung LW, Lao TT, Suen SS, Chan OK, Lau TK, Ngai KL, Chan PK, Leung TY. Seroprevalence of varicella zoster virus among pregnant women in Hong Kong: comparison with self-reported history. Vaccine. 2011 Oct 26;29(46):8186-8. doi: 10.1016/j.vaccine.2011.08.090. Epub 2011 Sep 10.

    PMID: 21911021BACKGROUND
  • Pourahmad M, Davami MH, Jahromi AR. Evaluation of anti-varicella antibody in young women before their marriage: A sero-epidemiologic study in Iran. J Clin Virol. 2010 Aug;48(4):260-3. doi: 10.1016/j.jcv.2010.04.015. Epub 2010 Jun 9.

    PMID: 20538515BACKGROUND
  • Perella D, Fiks AG, Jumaan A, Robinson D, Gargiullo P, Pletcher J, Forke CM, Schmid DS, Renwick M, Mankodi F, Watson B, Spain CV. Validity of reported varicella history as a marker for varicella zoster virus immunity among unvaccinated children, adolescents, and young adults in the post-vaccine licensure era. Pediatrics. 2009 May;123(5):e820-8. doi: 10.1542/peds.2008-3310.

    PMID: 19403475BACKGROUND
  • Koturoglu G, Kurugol Z, Turkoglu E. Seroepidemiology of varicella-zoster virus and reliability of varicella history in Turkish children, adolescents and adults. Paediatr Perinat Epidemiol. 2011 Jul;25(4):388-93. doi: 10.1111/j.1365-3016.2010.01180.x. Epub 2011 Apr 3.

    PMID: 21649681BACKGROUND
  • Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet. 1994 Jun 18;343(8912):1548-51. doi: 10.1016/s0140-6736(94)92943-2.

    PMID: 7802767BACKGROUND
  • Breuer J, Schmid DS, Gershon AA. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella. J Infect Dis. 2008 Mar 1;197 Suppl 2:S147-51. doi: 10.1086/529448.

    PMID: 18419389BACKGROUND
  • Maple PA, Rathod P, Smit E, Gray J, Brown D, Boxall EH. Comparison of the performance of the LIAISON VZV-IgG and VIDAS automated enzyme linked fluorescent immunoassays with reference to a VZV-IgG time-resolved fluorescence immunoassay and implications of choice of cut-off for LIAISON assay. J Clin Virol. 2009 Jan;44(1):9-14. doi: 10.1016/j.jcv.2008.08.012. Epub 2008 Sep 27.

    PMID: 18823815BACKGROUND
  • Sauerbrei A, Schafler A, Hofmann J, Schacke M, Gruhn B, Wutzler P. Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test. Clin Vaccine Immunol. 2012 Aug;19(8):1261-8. doi: 10.1128/CVI.00183-12. Epub 2012 Jun 20.

    PMID: 22718131BACKGROUND
  • Tischer A, Gassner M, Richard JL, Suter-Riniker F, Mankertz A, Heininger U. Vaccinated students with negative enzyme immunoassay results show positive measles virus-specific antibody levels by immunofluorescence and plaque neutralisation tests. J Clin Virol. 2007 Mar;38(3):204-9. doi: 10.1016/j.jcv.2006.12.017. Epub 2007 Feb 7.

    PMID: 17289430BACKGROUND
  • Mancuso JD, Krauss MR, Audet S, Beeler JA. ELISA underestimates measles antibody seroprevalence in US military recruits. Vaccine. 2008 Sep 8;26(38):4877-8. doi: 10.1016/j.vaccine.2008.06.028. Epub 2008 Jun 27.

    PMID: 18586062BACKGROUND
  • Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Zhang JX, Maupin TJ, Goldman GS, Tabony LJ, Brodovicz KG, Jumaan AO, Wharton M. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002 Feb 6;287(5):606-11. doi: 10.1001/jama.287.5.606.

    PMID: 11829699BACKGROUND

Study Officials

  • Olivier Picone, MD

    Service Gynécologie Hopital Foch

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 12, 2016

First Posted

May 17, 2016

Study Start

March 30, 2015

Primary Completion

July 26, 2020

Study Completion

July 26, 2020

Last Updated

August 25, 2020

Record last verified: 2019-08

Data Sharing

IPD Sharing
Will not share

Locations